Janux Therapeutics JANX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's financing cash flow?
- Janux Therapeutics (JANX) reported financing cash flow of $3.55M in Q1 2026.
- How has Janux Therapeutics's financing cash flow changed year-over-year?
- Janux Therapeutics's financing cash flow increased by 539.9% year-over-year, from $554K to $3.55M.
- What is the long-term trend for Janux Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), Janux Therapeutics's financing cash flow has grown at a -66.4% compound annual growth rate (CAGR), from $387.37M to $4.95M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.